Advances in the Treatment of Kidney and Upper Urinary Tract Cancers
Kidney and Upper Tract Urinary Cancers (UTUCs) are diseases of increasing population coverage, the treatment of which is undergoing a continuous process of evolution. A characteristic feature of renal cell cancer (RCC) treatment is the significant heterogeneity of patients (including different stage...
محفوظ في:
| التنسيق: | Online |
|---|---|
| اللغة: | الإنجليزية |
| منشور في: |
MDPI - Multidisciplinary Digital Publishing Institute
2024
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | ONIX_20240514_9783725805532_307 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1869527618624159744 |
|---|---|
| collection | Directory of Open Access Books |
| description | Kidney and Upper Tract Urinary Cancers (UTUCs) are diseases of increasing population coverage, the treatment of which is undergoing a continuous process of evolution. A characteristic feature of renal cell cancer (RCC) treatment is the significant heterogeneity of patients (including different stages of local advancement and different locations of metastases). Importantly, it is estimated that up to 30% of newly diagnosed RCC cases are patients with disseminated disease at the time of diagnosis. Therefore, predicting the response to modern treatment remains the unmet need of modern urologic oncology. Recent advancements in systematic treatment, i.e., immunotherapy, shed additional light on adjuvant treatment to be implemented in new clinical scenarios, including localized disease. |
| format | Online |
| id | doab-20.500.12854ir-137710 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2024 |
| publishDateRange | 2024 |
| publishDateSort | 2024 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-1377102024-05-14T14:12:44Z Advances in the Treatment of Kidney and Upper Urinary Tract Cancers Zapała, Łukasz Rajwa, Pawel renal cell carcinoma risk models survival analysis charlson comorbidity index systemic inflammatory markers upper tract urothelial carcinoma UTUC sPD-L1 soluble programmed death ligand-1 biomarker prognosis immune checkpoint inhibitor therapy chemotherapy radical nephroureterectomy focal therapy kidney cancer thermal ablation renal carcinoma RCC PD-1 PD-L1 nivolumab kidney tumor systemic inflammatory response syndrome nephrectomy globotriaosylceramide rhamnose-binding lectin sunitinib brain metastases neurosurgery targeted therapy basement membrane diagnostic renal cancer lncRNA prognostic model immunotherapy prostate cancer transplant immunosuppression progression metastatic prostate cancer upper tract urothelial cancer Balkan endemic nephropathy morphology CKs CD44 tyrosine kinase inhibitors (TKI) cabozantinib metastatic renal cell carcinoma (mRCC) adverse events predictive factor n/a thema EDItEUR::P Mathematics and Science::PB Mathematics::PBW Applied mathematics Kidney and Upper Tract Urinary Cancers (UTUCs) are diseases of increasing population coverage, the treatment of which is undergoing a continuous process of evolution. A characteristic feature of renal cell cancer (RCC) treatment is the significant heterogeneity of patients (including different stages of local advancement and different locations of metastases). Importantly, it is estimated that up to 30% of newly diagnosed RCC cases are patients with disseminated disease at the time of diagnosis. Therefore, predicting the response to modern treatment remains the unmet need of modern urologic oncology. Recent advancements in systematic treatment, i.e., immunotherapy, shed additional light on adjuvant treatment to be implemented in new clinical scenarios, including localized disease. 2024-05-14T14:12:37Z 2024-05-14T14:12:37Z 2024 book ONIX_20240514_9783725805532_307 9783725805532 9783725805549 https://directory.doabooks.org/handle/20.500.12854/137710 eng application/octet-stream Attribution-NonCommercial-NoDerivatives 4.0 International https://mdpi.com/books/pdfview/book/8935 https://mdpi.com/books/pdfview/book/8935 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-7258-0554-9 10.3390/books978-3-7258-0554-9 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783725805532 9783725805549 174 open access |
| spellingShingle | renal cell carcinoma risk models survival analysis charlson comorbidity index systemic inflammatory markers upper tract urothelial carcinoma UTUC sPD-L1 soluble programmed death ligand-1 biomarker prognosis immune checkpoint inhibitor therapy chemotherapy radical nephroureterectomy focal therapy kidney cancer thermal ablation renal carcinoma RCC PD-1 PD-L1 nivolumab kidney tumor systemic inflammatory response syndrome nephrectomy globotriaosylceramide rhamnose-binding lectin sunitinib brain metastases neurosurgery targeted therapy basement membrane diagnostic renal cancer lncRNA prognostic model immunotherapy prostate cancer transplant immunosuppression progression metastatic prostate cancer upper tract urothelial cancer Balkan endemic nephropathy morphology CKs CD44 tyrosine kinase inhibitors (TKI) cabozantinib metastatic renal cell carcinoma (mRCC) adverse events predictive factor n/a thema EDItEUR::P Mathematics and Science::PB Mathematics::PBW Applied mathematics Advances in the Treatment of Kidney and Upper Urinary Tract Cancers |
| title | Advances in the Treatment of Kidney and Upper Urinary Tract Cancers |
| title_full | Advances in the Treatment of Kidney and Upper Urinary Tract Cancers |
| title_fullStr | Advances in the Treatment of Kidney and Upper Urinary Tract Cancers |
| title_full_unstemmed | Advances in the Treatment of Kidney and Upper Urinary Tract Cancers |
| title_short | Advances in the Treatment of Kidney and Upper Urinary Tract Cancers |
| title_sort | advances in the treatment of kidney and upper urinary tract cancers |
| topic | renal cell carcinoma risk models survival analysis charlson comorbidity index systemic inflammatory markers upper tract urothelial carcinoma UTUC sPD-L1 soluble programmed death ligand-1 biomarker prognosis immune checkpoint inhibitor therapy chemotherapy radical nephroureterectomy focal therapy kidney cancer thermal ablation renal carcinoma RCC PD-1 PD-L1 nivolumab kidney tumor systemic inflammatory response syndrome nephrectomy globotriaosylceramide rhamnose-binding lectin sunitinib brain metastases neurosurgery targeted therapy basement membrane diagnostic renal cancer lncRNA prognostic model immunotherapy prostate cancer transplant immunosuppression progression metastatic prostate cancer upper tract urothelial cancer Balkan endemic nephropathy morphology CKs CD44 tyrosine kinase inhibitors (TKI) cabozantinib metastatic renal cell carcinoma (mRCC) adverse events predictive factor n/a thema EDItEUR::P Mathematics and Science::PB Mathematics::PBW Applied mathematics |
| topic_facet | renal cell carcinoma risk models survival analysis charlson comorbidity index systemic inflammatory markers upper tract urothelial carcinoma UTUC sPD-L1 soluble programmed death ligand-1 biomarker prognosis immune checkpoint inhibitor therapy chemotherapy radical nephroureterectomy focal therapy kidney cancer thermal ablation renal carcinoma RCC PD-1 PD-L1 nivolumab kidney tumor systemic inflammatory response syndrome nephrectomy globotriaosylceramide rhamnose-binding lectin sunitinib brain metastases neurosurgery targeted therapy basement membrane diagnostic renal cancer lncRNA prognostic model immunotherapy prostate cancer transplant immunosuppression progression metastatic prostate cancer upper tract urothelial cancer Balkan endemic nephropathy morphology CKs CD44 tyrosine kinase inhibitors (TKI) cabozantinib metastatic renal cell carcinoma (mRCC) adverse events predictive factor n/a thema EDItEUR::P Mathematics and Science::PB Mathematics::PBW Applied mathematics |
| url | ONIX_20240514_9783725805532_307 |